Gufic BioSciences
356.65
-7.85(-2.15%)
Market Cap₹3,576.40 Cr
PE Ratio59.20
IndustryHealthcare
Company Performance:
1D-2.15%
1M-4.69%
6M+4.42%
1Y-8.79%
5Y+337.07%
View Company Insightsright
Latest news about Gufic BioSciences
Gufic Biosciences Reports Q1 Results: Revenue Up, Profit Down Amid Rising Costs Aug 13, 2025
Gufic BioSciences, an Indian pharmaceutical company, released its Q1 financial results. Consolidated revenue increased by 10.3% to ₹223.72 crore, up from ₹202.81 crore in the previous year. However, net profit declined by 37.3% to ₹13.07 crore from ₹20.86 crore. EBITDA decreased by 9.8% to ₹32.30 crore, with the EBITDA margin falling by 339 basis points to 14.25%. The company faced increased material costs, higher employee benefits expenses, and doubled finance costs. Gufic BioSciences continues to operate solely in the pharmaceuticals segment.
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down May 30, 2025